NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
14 trialsNCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT05749211 2023-05-16
Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer
Ruijin Hospital
Phase NA Unknown
NCT05641506 2022-12-07
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05311579 2022-04-13
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05187208 2022-01-26
POLO
Seoul National University Hospital
Phase 4 Unknown
NCT05044091 2021-09-14
HOPEI
Jiangsu Cancer Institute & Hospital
Unknown
NCT04217798 2021-09-01
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT04885413 2021-08-23
An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients
Sun Yat-sen University
Phase 2 Unknown
NCT04986371 2021-08-02
RENI-1
ChineseAMS
Unknown
NCT04582552 2021-01-20
ROMP
Jiangsu Cancer Institute & Hospital
Unknown
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown
NCT03895788 2019-03-29
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
Hunan Cancer Hospital
Phase 1 Unknown